(Q37034189)

English

The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo

scientific article published on January 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

17 August 2017

The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo (English)

1 reference

Europe PubMed Central

17 August 2017

1 reference

ChEBI release 2020-05-28

6

object named as

Shmuel Yaccoby

1 reference

Europe PubMed Central

17 August 2017

Maurizio Zangari

5

object named as

Maurizio Zangari

1 reference

Europe PubMed Central

17 August 2017

author name string

Angela Pennisi

1

1 reference

Europe PubMed Central

17 August 2017

Xin Li

2

1 reference

Europe PubMed Central

17 August 2017

Wen Ling

3

1 reference

Europe PubMed Central

17 August 2017

Sharmin Khan

4

1 reference

Europe PubMed Central

17 August 2017

publication date

1 January 2009

1 reference

Europe PubMed Central

17 August 2017

American Journal of Hematology

1 reference

Europe PubMed Central

17 August 2017

84

1 reference

Europe PubMed Central

17 August 2017

1

1 reference

Europe PubMed Central

17 August 2017

6-14

1 reference

Europe PubMed Central

17 August 2017

Role of decorin in the antimyeloma effects of osteoblasts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2612734

29 September 2017

Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2612734

29 September 2017

Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2612734

29 September 2017

Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2612734

29 September 2017

Atacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2612734

29 September 2017

Establishment and exploitation of hyperdiploid and non-hyperdiploid human myeloma cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2612734

29 September 2017

New drugs for myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2612734

29 September 2017

Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2612734

29 September 2017

Response to bortezomib and activation of osteoblasts in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2612734

29 September 2017

Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2612734

29 September 2017

Role of osteoblast suppression in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2612734

29 September 2017

The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2612734

29 September 2017

Mechanisms of bone metastasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2612734

29 September 2017

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2612734

29 September 2017

New Insights in Myeloma-induced Osteolysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2612734

29 September 2017

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2612734

29 September 2017

Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2612734

29 September 2017

Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2612734

29 September 2017

Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2612734

29 September 2017

Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2612734

29 September 2017

The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2612734

29 September 2017

Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2612734

29 September 2017

Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2612734

4 September 2018

Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2612734

4 September 2018

Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2612734

4 September 2018

Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2612734

4 September 2018

Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2612734

4 September 2018

Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2612734

4 September 2018

Cancer and the microenvironment: myeloma-osteoclast interactions as a model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2612734

4 September 2018

Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2612734

4 September 2018

Toxic acute tubular necrosis following treatment with zoledronate (Zometa).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2612734

4 September 2018

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2612734

4 September 2018

Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2612734

4 September 2018

Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-?B ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2612734

4 December 2018

The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/18980173

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The proliferative potential of myeloma plasma cells manifest in the SCID-hu host

1 reference

https://pubmed.ncbi.nlm.nih.gov/18980173

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18980173

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18980173

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/18980173

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations

1 reference

https://pubmed.ncbi.nlm.nih.gov/18980173

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/18980173

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Maintenance therapy with thalidomide improves survival in patients with multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18980173

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibin A is an endocrine stimulator of bone mass and strength

1 reference

https://pubmed.ncbi.nlm.nih.gov/18980173

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/AJH.21310

1 reference

Europe PubMed Central

17 August 2017

1 reference

Europe PubMed Central

17 August 2017

1 reference

Europe PubMed Central

17 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37034189&oldid=2116820201"